R-848

CHF 80.00
In stock
AG-CR1-3582-M0055 mgCHF 80.00
AG-CR1-3582-M02525 mgCHF 320.00
More Information
Product Details
Synonyms Resiquimod; S 28463; R848
Product Type Chemical
Properties
Formula

C17H22N4O2

MW 314.4
CAS 144875-48-9
Source/Host Chemicals Synthetic.
Purity Chemicals ≥98%
Appearance White to off-white powder.
Solubility Soluble in DMSO, dichloromethane or methanol. Slightly soluble in acetonitrile or ethyl acetate.
InChi Key BXNMTOQRYBFHNZ-DZQCGVKKCS
Smiles CCOCC1=NC2=C(N1CC(C)(C)O)C1=C(C=CC=C1)N=C2N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Stock solutions are stable for at least 3 months when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Immune response modifier. Potent antitumor and antiviral compound [1, 3, 10, 11, 13, -16].
  • Stimulates antibody secretion and cytokine production [2].
  • Used as adjuvant to increase the effectiveness of vaccines [2, 7, 9, 10].
  • Potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human [4-6].
  • Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-κB [4].
  • NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I [8].
  • Upregulator of the opioid growth factor receptor [12].
  • Used in the treatment of skin lesions such as herpes simplex virus [16].
Product References
  1. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod: T.L. Wagner, et al.; Cell Immunol. 191, 10 (1999)
  2. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN: J.P. Vasilakos, et al.; Cell Immunol. 204, 64 (2000)
  3. The immune response modifier resiquimod mimics CD40-induced B cell activation: G.A. Bishop, et al.; Cell. Immunol. 208, 9 (2001)
  4. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002)
  5. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848: M. Jurk, et al.; Nat. Immunol. 3, 499 (2002)
  6. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8: K.B. Gorden, et al.; J. Immunol. 174, 1259 (2005)
  7. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848): R.D. Weeratna, et al.; Vaccine 23, 5263 (2005)
  8. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3: T.D. Kanneganti, et al.; Nature 440, 233 (2006)
  9. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination: R. Ma, et al.;  BBRC 361, 537 (2007)
  10. Resiquimod and other immune response modifiers as vaccine adjuvants: M.A. Tomai, et al.; Expert Rev. Vaccines 6, 835 (2007) (Review)
  11. The antiviral activity of Toll-like receptor 7 and 7/8 agonists: R.L. Miller, et al.; Drug News Perspect. 21, 69 (2008) (Review)
  12. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function: I.S. Zagon, et al.; Exp. Biol. Med. 233, 968 (2008)
  13. Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation: W. van den Ancker, et al.; Cancer Immunol. Immunother. 60, 37 (2011)
  14. Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms: L.P. Van, et al.; Eur. J. Immunol. 41, 1992 (2011)
  15. R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes: H. Nian, et al.; BMC Infect. Dis. 12, 5 (2012)
  16. Resiquimod|a topical drug for viral skin lesions and skin cancer: T. Meyer, et al.; Expert Opin. Investig. Drugs 22, 149 (2013)
  17. TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation: D.E. Tuipulotu, et al.; Antimicrob. Agents Chemother. 62, e02417 (2018)
  18. Systemic and intestinal porcine epidemic diarrhea virus-specific antibody response and distribution of antibody-secreting cells in experimentally infected conventional pigs: Vet. Res. 52, 2 (2021)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.